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Mandibular positioning techniques to improve 
sleep quality in patients with obstructive sleep 
apnea: current perspectives
Sofie Wilkens Knappe 
Liselotte Sonnesen
Section of Orthodontics, Department 
of Odontology, Faculty of Health 
and Medical Sciences, University of 
Copenhagen, Copenhagen, Denmark
Abstract: The purpose of this article is to review 1) mandibular advancement device (MAD) – 
indication, treatment success, and side effects; 2) maxillomandibular advancement (MMA) 
surgery of the jaws – indication, treatment success, and side effects; and 3) current perspectives. 
Both MAD and MMA are administered to increase the upper airway volume and reduce the col-
lapsibility of the upper airway. MAD is noninvasive and is indicated as a first-stage treatment in 
adult patients with mild-to-moderate obstructive sleep apnea (OSA) and in patients with severe 
OSA unable to adhere to continuous positive airway pressure (CPAP). MAD remains inferior to 
CPAP in reducing the apnea–hypopnea index (AHI) with a treatment success ranging between 
24% and 72%. However, patient compliance to MAD is greater, and with regard to subjective 
sleepiness and health outcomes, MAD and CPAP have been found to be similarly effective. 
Short-term side effects of MAD are minor and often transient. Long-term side effects primarily 
appear as changes in the dental occlusion related to decreases in overjet and overbite. MMA 
is efficacious but highly invasive and indicated as a second-stage treatment in patients with 
moderate-to-severe OSA, with prior failure to other treatment modalities or with craniofacial 
abnormalities. The surgical success and cure rates are found to be 86.0% and 43.2%, respectively. 
Side effects may appear as postsurgical complications such as temporary facial paresthesia and 
compromised facial esthetics. However, most patients report satisfaction with their postsurgical 
appearance. Both treatment modalities require experienced clinicians and multidisciplinary 
approaches in order to efficaciously treat OSA patients. Some researchers do propose possible 
predictors of treatment success, but clear patient selection criteria and clinical predictive values 
for treatment success are still needed in both treatment modalities.
Keywords: sleep-disordered breathing, mandibular advancement treatment, treatment outcome
Introduction
Obstructive sleep apnea (OSA) is a multifactorial disease with age, gender, and body 
mass index (BMI) as predisposing factors.1 OSA is classified as a common sleep- and 
breath-related disease, with an estimated prevalence of 2%–4% in the adult popula-
tion.1 The disease is chronic and progressive in nature, and the prevalence in men aged 
≥60 years is as high as 30%–60%.2 Furthermore, the disease is more common in men 
than in women.2 OSA is caused by a central, sleep-induced neuromuscular hypotonia 
which, combined with a decreased space in the pharynx due to anatomical reasons, 
causes inspirational collapse of the upper airways during sleep.1,3,4 A collapse obstructs 
the airways and inhibits ventilation, which results in reduction (hypopnea) or cessation 
(apnea) of airflow.1,3 This obstruction of the airflow leads to continued and exacerbated 
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respiratory efforts.1,3 An apnea lasts ≥10 seconds and causes 
hypoxemia and hypercapnia that lead to arousals with auto-
nomic activation and reestablishment of the ventilation.1,4,5 
Repetitive arousals cause changes in the sleep pattern with 
reduced rapid eye movement (REM) sleep and restorative 
non-REM slow-wave sleep.4 This leads to increased morbid-
ity and mortality in patients with OSA.6,7
The primary symptoms of OSA are loud snoring and 
excessive daytime sleepiness.3 Furthermore, nightly chok-
ing or gasping, nocturia, morning headache, memory loss, 
decreased concentration, and increased irritability are also 
reported.5 Studies have shown correlations among OSA and 
numerous cardiovascular diseases such as systemic hyper-
tension, apoplexy, treatment refractory hypertension, and 
type 2 diabetes mellitus.4,8,9 It is still questionable whether 
OSA is an independent risk factor for these diseases, or if 
the diseases occur along with the establishment of OSA, 
since OSA patients are often obese and show signs of the 
metabolic syndrome.10 However, OSA has negative effects 
on the quality of life, working ability, and traffic safety along 
with comorbidities such as systemic hypertension threatening 
the patient survival.1,3,5,6
The diagnostic criteria of OSA are determined during 
a comprehensive sleep evaluation and are based on clinical 
signs and symptoms.5 The patients undergo polysomnogra-
phy (PSG), where the amount of apneas and hypopneas per 
hour (the apnea–hypopnea index [AHI]) is measured.7 OSA 
in adults is classified as mild (AHI≥5 but <15), moderate 
(AHI≥15 but <30), or severe (AHI≥30).6,11
Due to the nature of OSA, the disease is often only 
treated symptomatically.7,12 The primary treatment options 
in adults are physical and consist of continuous positive 
airway pressure (CPAP), mandibular advancement device 
(MAD) treatment, and upper airway surgery.1,5 Failure to 
adhere or respond to any of the primary treatment options 
may indicate maxillomandibular advancement (MMA) 
surgery as a treatment option.13,14 CPAP is the gold standard 
treatment option for OSA.15 CPAP pneumatically splints open 
the airway, which is highly efficacious in preventing upper 
airway collapse and hence in reducing the AHI and subjective 
sleepiness.15 Unfortunately, the acceptance, tolerance, and 
adherence to CPAP are often low among the patients, thus 
reducing the effectiveness of the treatment.15
OSA patients intolerant to CPAP treatment need to 
be offered other treatment options in order to reduce the 
increased risk of morbidity and mortality.14,16 The overall 
aim of this paper is to discuss mandibular positioning tech-
niques including MAD treatment and MMA surgery for the 
 treatment of OSA in adults. Indication, treatment success, and 
side effects of MAD treatment and MMA surgery in patients 
with OSA are described in the following sections. Further-
more, we discuss the current perspectives of MAD treatment 
and MMA surgery in adult patients suffering from OSA.
MAD treatment
Indication
A MAD is a removable, intraoral dental splint used to 
protrude the mandible in a forward position and therefore 
enlarge the upper airway.17 It represents the main non-CPAP 
treatment in adult OSA patients.18 When MAD is inserted 
into the mouth, it works directly by enlarging the pharyngeal 
airway primarily in the velopharyngeal and oropharyngeal 
areas due to stretching of the pharyngeal soft tissues attached 
to the mandible.17–19 This reduces the upper airway collaps-
ibility by altering the upper airway morphology, structure, 
and function.3,5,17 In addition, MAD treatment may influence 
the neuromuscular function in the upper airway.17 Prior to 
MAD treatment, it is essential that the dentist performs a 
screening and an examination of the oral health, dental status 
including occlusion, and the orofacial function including 
the temporomandibular joints (TMDs) in order to exclude 
patients at high risk of unwanted side effects or patients for 
whom MAD treatment is contraindicated.20 When MAD 
treatment is carried out by qualified and experienced dentists 
with regular follow-ups, MAD can be used during sleep for 
years, but the effectiveness is usually inferior to CPAP, and 
hence, MAD treatment is indicated in patients with1,5,6,17,20
•	 mild-to-moderate OSA.
•	 severe OSA unable to tolerate or adhere to CPAP 
treatment.
MAD treatment has for a long time been an alternative to 
CPAP treatment in mild-to-moderate OSA patients, provided 
that the objective treatment response of MAD treatment is 
sufficient.1,5,18 However, due to similar treatment responses to 
MAD and CPAP treatments in the mild and moderate OSA 
severity, MAD may be offered as a first-line treatment in 
these patients.17 Furthermore, MAD has been proven to be 
effective in reducing the AHI in patients with severe OSA,21 
and hence, MAD is indicated in severe OSA patients who 
have failed adherence to CPAP.6,17,18
The MAD is primarily administered to patients with 
20 teeth or more, with a bone loss of <50% and evenly 
distributed occlusal tooth contact,22 but the device may also 
be manufactured for patients with less teeth and for even 
edentulous patients.23,24 The MAD should preferably be used 
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the whole night, at least for 4 hours each night, and at least 
70% of the nights.25 The recommended advancement of the 
mandible has been reported to be 50%–75% of the maximal 
advancement of the mandible and >6 mm, depending on the 
severity of OSA.26–29
Treatment success
The effect of MAD treatment is measured in terms of AHI 
reduction.6,15 The treatment success varies due to different 
MAD treatment protocols and patient inclusion criteria. 
The treatment success is typically expressed as a ≥50% AHI 
reduction from baseline, resulting in a treatment outcome 
with an AHI of <10 events/h.15 It is reported that the MAD 
treatment can reduce AHI up to 76% in patients with mild-
to-moderate OSA30 and 79% in patients with severe OSA.30 
However, in general, it is reported that the mean reduction 
in AHI ranges between 24% and 72% and that the mean pro-
portion of patients who achieve a posttreatment AHI of <5 
ranges between 29% and 71%.31 However, the apnea reduc-
tion of MAD treatment may be smaller and more variable 
compared with CPAP treatment.15,20 A success rate defined 
as a posttreatment AHI of <10 events/h has been found to 
range from 30% to 85% for MAD and from 62% to 100% for 
CPAP.15 However, adherence to MAD has been reported to be 
76%–95%, which is superior compared to CPAP adherence 
ranging from 30% to 80%.30 This finding may explain why 
the effectiveness of MAD treatment has been found to be 
similar to CPAP treatment with regard to subjective sleepiness 
and health outcomes, such as blood pressure, microvascular 
reactivity, cardiac function,  symptoms, quality of life, and 
driving performance.6,15,17,18,20 Phillips et al, who conducted 
a randomized controlled trial regarding health outcomes of 
CPAP vs MAD treatment, also found important health out-
comes (such as sleepiness, driving simulator performance, 
and disease-specific quality of life) to be similar after 1 month 
of optimal CPAP or MAD treatment in moderate-to-severe 
OSA patients and attributed it to the fact that MAD is superior 
in compliance relative to CPAP.32 Furthermore, compared 
with placebo devices in patients with mild-to-moderate 
OSA, the MAD treatment reduces sleep apnea and subjec-
tive daytime sleepiness, and improves quality of life in OSA 
patients.15,18,21,33
Success with MAD treatment may be predicted by 
patient-specific factors, such as female gender, younger age, 
supine-dependent OSA, lower BMI, smaller neck circumfer-
ence, and craniofacial factors.17,19 A cephalometric pilot study 
found that retrognathia of the jaws is a positive predictive 
factor for MAD treatment success.19 Furthermore, it was 
found that OSA patients with morphological deviations in the 
upper cervical spine, such as fusion of two or more cervical 
vertebrae, may respond poorer to MAD treatment.19 Hoekema 
et al34 investigated the predictors of treatment outcome for 
CPAP and MAD treatments, and found that MAD treatment 
was favorable in OSA patients with certain craniofacial char-
acteristics that primarily relate to mandibular retrognathia. 
However, some studies have also found less effect of MAD 
in supine-dependent OSA35 and inconclusive cephalometric 
parameters leading to their conclusion that outlying cepha-
lometric parameters might be observed as contraindicators 
or “red flags” rather than predictive markers.36 Therefore, no 
clinically reliable and validated method for the prediction of 
MAD treatment success has been established so far.17 Further 
interdisciplinary research in this field is therefore necessary.
Side effects
MAD treatment is generally well tolerated by OSA patients.17 
However, short-term and long-term side effects may occur. 
Short-term side effects are mainly minor and transient and 
often end within the adaptation period which may last for 
a few months.15,17,18 The short-term side effects may appear 
as discomfort and tenderness of the teeth, temporoman-
dibular joint pain, myofascial pain, dryness of the mouth, 
excessive salivation and drooling as well as irritation of the 
gingiva.3,15,17,18,37 In contrast, long-term side effects may last 
throughout the entire treatment and only cease with termina-
tion of the treatment.38 Long-term side effects may appear as 
changes in the dental occlusion related to decreases in overjet 
and overbite and minor skeletal changes related to an increase 
in face height and downward rotation of the mandible.15 One 
study on 77 OSA patients after an observation period of a 
decade with continued MAD treatment found long-term 
changes in dental occlusion to be progressive in nature.39 
They found a significant change in the relationship between 
the upper and lower arches where a decrease in the overbite 
and overjet was observed.39 This corresponds to the findings 
of a randomized controlled study, where a decrease in the 
overbite and overjet occurred after 2 years of MAD treatment 
in OSA patients compared to those treated with CPAP.37 
Furthermore, they observed a decrease in occlusal contact 
points in the premolar region with a tendency toward a mesial 
occlusion (Class III occlusion) in these patients, indicating 
that the mandible moves toward a more anterior position.37
The side effects may develop due to the reciprocal forces 
distributed throughout the dentoalveolar and skeletal struc-
tures with the MAD in situ.37,39 The mandibular incisors are 
directed labially, and the maxillary incisors are directed 
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palatally due to the attempt of the mandible to return to a 
more dorsal position.3,37,40 Skeletal changes are undesirable 
and normally do not occur in adult OSA patients because 
the growth has ceased.41–43 Therefore, due to the protruded 
jaw position, MAD treatment in OSA patients may induce 
changes in the dental occlusion, TMJs, masticatory muscles, 
and orofacial function.3,22,39,44 However, side effects seri-
ous enough to cause patients to discontinue treatment are 
less likely in MAD treatment compared to CPAP therapy.20 
Furthermore, with careful control, adjustments of the MAD, 
and follow-ups by a dentist or dental specialist experienced 
in the field of orthodontics and oral physiology, side effects 
to MAD treatment have shown to be less harmful than previ-
ously perceived.20,22,37
MMA surgery
Indication
MMA surgery involves LeFort I maxillary and sagittal split 
mandibular osteotomies and is the most effective craniofacial 
surgical technique for the treatment of OSA in adults.13,45 
MMA surgery is carried out to enlarge the pharyngeal airway 
dimension at multiple anatomic levels, namely, the nasophar-
ynx, oropharynx, and hypopharynx, by expanding the facial 
skeletal framework on which the pharyngeal soft tissues and 
the tongue are attached.45–47 This reduces the inspirational 
collapsibility due to a physical expansion of the pharynx and 
the increase in tension of the pharyngeal soft tissues.12,13,45,48 
Anterior advancement of the maxilla not only expands the 
retropalatal airway but also may help to suspend the tongue 
forward due to a tension in the palatoglossal muscle.47 
Similarly, anterior advancement of the mandible directly 
enlarges the retrolingual airway by moving the tongue base 
in an anterior direction.47 In a comparative study of OSA 
patients and normal controls, Butterfield et al49 found that 
MMA improves the anatomy of the airways in OSA patients 
leading to an anatomy closer to that of the normal population. 
Furthermore, a review of observational studies indicates that 
there might be a direct relationship between the magnitude of 
MMA and an increased volume in the upper airway showing 
that MMA surgery may effectively increase the upper airway 
volume.50 However, MMA has a good long-term gain in the 
anterior–posterior direction but limited gain in the lateral 
dimension of the pharyngeal airway, which is one of the 
limitations of MMA.13
The candidates for MMA surgery include adults and 
adolescents whose ossification of cranial structures is com-
plete with14,45,46
•	 moderate or severe OSA (AHI>15).
•	 prior failure or no toleration of other therapeutic interven-
tions, such as upper airway surgery, MAD, or CPAP.
•	 craniofacial abnormalities (eg, micrognathia or maxil-
lomandibular hypoplasia).
However, it is important to determine if the patient is a can-
didate for other treatments, eg, lifestyle modification, weight 
loss, MAD for mild OSA, and bariatric surgery for extremely 
obese patients (BMI>35).46,47
Treatment success
Due to the OSA etiology as a chronic disease, the positive 
MMA treatment outcomes are defined as either OSA cure 
(AHI<5) or treatment success (AHI<20 and ≥50% reduc-
tion in AHI).12 According to Holty and Guilleminault,45 who 
performed a meta-analysis of 22 studies of MMA describing 
627 adults with OSA, MMA is a highly effective and safe 
treatment for OSA in adults. They found the surgical success 
rate (AHI<20 and ≥50% reduction in AHI) to be 86.0% and 
the surgical cure rate (AHI<5) to be 43.2% postoperative. 
Another meta-analysis of MMA treatment in OSA patients 
also observed a reduction in AHI and an increase in the low-
est oxygen saturation, indicating treatment success.51 Most 
OSA patients report subjective satisfaction after MMA with 
improvement in OSA symptomatology (excessive daytime 
sleepiness, morning headache, memory loss, and impaired 
concentration) as well as in qualities of life  measures.45 A 
cohort study on the long-term effectiveness and safety of 
MMA for the treatment of OSA showed successful out-
comes with minimal long-term treatment-related adverse 
outcomes.14 They found reductions in the AHI, diastolic blood 
pressure, and subjective sleepiness scored in the Epworth 
Sleepiness Scale (ESS) along with improvements in quality-
of-life measurements. The outcomes of MMA surgery appear 
to be equivalent to the outcomes of patients who fully adhere 
to and show great compliance with CPAP.14 Therefore, they 
suggest that MMA surgery should be considered as an alter-
native treatment of choice to patients with severe OSA unable 
to adhere to CPAP.14 However, few patients may experience 
relapse in AHI and ESS after a while.52 Perhaps, this can be 
attributed to the theory that OSA is a chronic, progressive 
disease causing continuous stretching and destroying of 
the pharyngeal soft tissues resulting in relapse of apneas in 
some patients.53
Patient-specific characteristics may determine whether 
MMA surgery will provide the patient with a successful 
outcome.13,45 The most reliable predictor of MMA surgery 
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outcome is preoperative OSA severity with less likelihood 
of achieving surgical success or surgical cure with the higher 
degree of OSA severity.13 In contrast, patients with the high-
est preoperative OSA severity are more likely to experience 
greater improvement postoperatively.13 This indicates that 
MMA surgery may be beneficial to OSA patients even 
though they have a high OSA severity. MMA surgery is 
not a cure for OSA but a treatment that can minimize the 
symptoms and multisystem damage as a result of OSA and 
thereby confer a mortality benefit.13,45 Reliable predictors of 
MMA treatment success are as follows: younger age, lower 
preoperative weight, and greater maxillary advancement.45 
In contrast, no evidence of a correlation exists between the 
magnitude of mandibular advancement and improvement 
in OSA outcome,45,54 although it is generally recommended 
that the magnitude of advancement of the maxilloman-
dibular complex to treat OSA should be ~10 mm, which 
is well beyond the typical range to correct malocclusion or 
dentofacial deformities and will cause significant changes 
in the facial appearance and orofacial function.47,55 There-
fore, patients need to be informed about possible unwanted 
esthetic changes prior to MMA surgery.47 Still, interdisciplin-
ary research is needed for detecting a clinical, reliable, and 
validated method for prediction of MMA treatment success.
Side effects
MMA is a highly invasive treatment with complications 
such as pain, swelling, malocclusion, poor cosmetic results, 
facial numbness (due to preoperative pressure or damage 
of the inferior alveolar nerve), tingling, jaw stiffness, and 
postoperative relapse of advancement.13 Complications of 
surgery can be divided into major and minor complications.45 
The major complication rate may be expected to be 1.0% and 
primarily includes incidents of cardiac arrest, dysrhythmia, 
and mandibular fracture.45 However, major complications are 
rare and mainly associated with older age and preoperative 
medical comorbidity.13 Surgical mortality is very rare and not 
reported in the current literature.13,45 The minor complication 
rate may be expected to be 3.1% and includes mostly minor 
hemorrhages or infections curable with antibiotics.45 Facial 
paresthesia is common (100%), but 85.8% of patients will 
stabilize 12 months postsurgery.45 Furthermore, the patients 
may experience malocclusion postsurgery, but in most cases 
these changes can be resolved with regular rehabilitation 
therapy which is expensive for the patients and requires 
lifelong maintenance.45
Like other craniofacial surgery treatments the patients 
require some days of hospitalization postsurgery. A meta-
analysis observed that the subjects required 3.5±3.5 days 
of hospitalization after MMA surgery for the treatment of 
OSA,45 which is also the expected time for patients undergo-
ing orthodontic surgery or surgery for correction of dento-
facial deformities.56,57
The skeletal stability is crucial in the long-term treatment 
outcome, and it may be expected that 10%–20% surgical 
relapse occurs in 15% of OSA patients after MMA, but 
without causing any worsening of the AHI.45 However, a 
clinical and cephalometric study found that advancement of 
the maxillomandibular complex for 10 mm remained stable,55 
which was comparable to another clinical study that also 
observed long-term skeletal stability after MMA surgery.12 
This might indicate that the advancement of the maxilloman-
dibular complex should be ~10 mm to gain long-term skeletal 
stability along with beneficial treatment outcomes in OSA 
patients. Unfortunately, due to the magnitude of advance-
ment of the maxillomandibular complex, facial esthetics 
and orofacial function may be compromised after surgery.47 
However, most patients report satisfaction, some patients 
are neutral, and few are dissatisfied with the facial esthetics 
after MMA surgery.47,58 To minimize the esthetic changes, the 
surgeon can perform different additive corrections such as 
suturing the alar base which minimizes the widening of the 
nasal base, anterior nasal spine reduction, and genioplasty 
with reduction of the chin prominence.47
Current perspectives
MAD is accepted as an efficacious first-stage treatment 
in patients with mild-to-moderate OSA.18,21 On the other 
hand, MMA surgery still remains a second-stage treatment 
available for patients with moderate-to-severe OSA even 
though it has been accepted as a safe and highly efficacious 
treatment of OSA.14,45 Like MAD treatment, MMA surgery 
is not a cure of OSA, but it can minimize the symptoms 
and multisystem damage as a result of OSA.13,45 Therefore, 
patients with residual/refractory AHI after other unsuccess-
ful surgical procedures or treatment modalities can most 
often benefit from MMA.13,14,47,58 Since CPAP therapy is 
still classified as the gold standard treatment of OSA, MAD 
and MMA surgery might be reserved for OSA patients who 
cannot (or will not) tolerate CPAP.4,11 However, in terms of 
the present research results, it is highly relevant to discuss 
whether each treatment modality ought to be considered as 
a first-stage option taking OSA severity and compliance 
of the patients into consideration. MAD treatment has, as 
previously mentioned, a greater patient compliance than 
CPAP therapy and hence may be almost as beneficial in the 
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treatment of OSA in mild-to-moderate disease and in some 
cases of severe OSA. Furthermore, as CPAP therapy, MAD 
treatment is noninvasive and with careful patient selection 
and MAD treatment protocol, it has been shown to be less 
harmful than previously perceived.22,37 In contrast, MMA 
surgery is a highly invasive treatment option and should 
therefore be considered carefully prior to treatment.13,46 In 
the literature, it is discussed whether MMA surgery ought 
to be a first-stage or second-stage treatment option for OSA 
patients without dentofacial deformities.12,14 Initially, MMA 
surgery was performed after failure of previous nasal and/or 
oropharyngeal surgery, but repeated research documenting 
beneficial treatment outcomes may underline the possibil-
ity to extend MMA surgery as a first-stage treatment for 
moderate-to-severe OSA patients.12,14,58 However, it must be 
emphasized that there is a great intraindividual variability of 
AHI measurements in OSA patients causing one night PSG 
measurement to be less reliable for evaluating treatment 
success compared to measurements based on consecutive 
nights.59 Most studies on MAD and MMA treatment effect 
rely on one-night PSG measurement pre- and posttreatment, 
which may cause difficulties in interpreting the actual treat-
ment effect and hence the treatment success described in 
such studies.59 However, MMA surgery is a permanent treat-
ment option with great results in long-term stability, which 
might be essential in patients with generally low treatment 
 compliance.58 Still, continuous follow-up of MMA-treated 
OSA patients is necessary in order to detect a possible relapse 
of disease severity and to control their lifestyle.12 Further-
more, for both treatment modalities, clear patient selection 
criteria and clinical predictive values for treatment success 
are still needed.
Conclusion
OSA cannot be cured and treatment choices such as MAD 
and MMA may be efficacious and beneficial alternatives to 
CPAP. Recent research indicates comparable treatment suc-
cess of MAD and CPAP in patients with mild-to-moderate 
OSA as well as beneficial effects in severe cases with mini-
mal and relatively harmless possible side effects. However, 
long-term MAD treatment may induce changes in the dental 
occlusion related to an increase in overjet and overbite. OSA 
patients with severe disease, craniofacial deformities, or 
low-treatment compliance may benefit from MMA surgery 
alternatively to CPAP. Current research shows great results 
of MMA in decreasing AHI in patients with both moderate-
to-severe OSA, which may underline the possibility to 
extend MMA surgery as a first-stage treatment option in 
these cases. However, it must be emphasized that MMA is 
a permanent and highly invasive treatment modality with 
common side effects such as facial paresthesia and changes 
in the facial esthetics as well as risks of surgical morbidity. 
Either treatment modality requires experienced clinicians and 
multidisciplinary approaches along with regular follow-ups 
in order to efficaciously treat OSA patients. Some research-
ers do propose possible predictors of treatment success, but 
clear patient selection criteria and clinical predictive values 
for treatment success are still needed in both treatment 
modalities.
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